Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,751 shares of the medical instruments supplier’s stock after acquiring an additional 165 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $1,869,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in BDX. WR Wealth Planners LLC lifted its stake in Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after buying an additional 42 shares in the last quarter. Clear Creek Financial Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the period. Central Pacific Bank Trust Division lifted its holdings in Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 45 shares during the last quarter. Finally, Tompkins Financial Corp increased its position in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.6 %

NYSE BDX opened at $224.00 on Friday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The firm has a 50 day moving average of $235.15 and a two-hundred day moving average of $234.54. The stock has a market capitalization of $64.74 billion, a PE ratio of 37.71, a price-to-earnings-growth ratio of 1.68 and a beta of 0.43. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the firm earned $3.42 earnings per share. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is presently 63.97%.

Analyst Ratings Changes

BDX has been the subject of a number of research analyst reports. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Raymond James reduced their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.